Log in

Odonate Therapeutics Stock Price, News & Analysis (NASDAQ:ODT)

$26.95
-1.10 (-3.92 %)
(As of 10/18/2019 04:00 PM ET)
Today's Range
$26.76
Now: $26.95
$28.29
50-Day Range
$24.46
MA: $28.08
$31.73
52-Week Range
$11.54
Now: $26.95
$43.75
Volume171,656 shs
Average Volume120,236 shs
Market Capitalization$867.52 million
P/E RatioN/A
Dividend YieldN/A
Beta1.77
Odonate Therapeutics, Inc, a pharmaceutical company, develops therapeutics for the treatment of cancer. It is developing tesetaxel, an orally administered chemotherapy agent, which is in Phase III clinical study for patients with locally advanced or metastatic breast cancer. The company was founded in 2013 and is based in San Diego, California.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ODT
CUSIPN/A
Phone858-731-8180

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$4.62 per share

Profitability

Net Income$-88,960,000.00

Miscellaneous

Employees117
Market Cap$867.52 million
Next Earnings Date10/22/2019 (Estimated)
OptionableNot Optionable

Receive ODT News and Ratings via Email

Sign-up to receive the latest news and ratings for ODT and its competitors with MarketBeat's FREE daily newsletter.


Odonate Therapeutics (NASDAQ:ODT) Frequently Asked Questions

What is Odonate Therapeutics' stock symbol?

Odonate Therapeutics trades on the NASDAQ under the ticker symbol "ODT."

How were Odonate Therapeutics' earnings last quarter?

Odonate Therapeutics Inc (NASDAQ:ODT) announced its quarterly earnings results on Wednesday, July, 24th. The company reported ($1.15) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.24) by $0.09. View Odonate Therapeutics' Earnings History.

When is Odonate Therapeutics' next earnings date?

Odonate Therapeutics is scheduled to release their next quarterly earnings announcement on Tuesday, October 22nd 2019. View Earnings Estimates for Odonate Therapeutics.

What is the consensus analysts' recommendation for Odonate Therapeutics?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Odonate Therapeutics in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Odonate Therapeutics.

Has Odonate Therapeutics been receiving favorable news coverage?

Press coverage about ODT stock has been trending somewhat negative recently, InfoTrie reports. InfoTrie identifies negative and positive press coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Odonate Therapeutics earned a news sentiment score of -1.5 on InfoTrie's scale. They also gave media coverage about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the stock's share price in the near term. View News Stories for Odonate Therapeutics.

Are investors shorting Odonate Therapeutics?

Odonate Therapeutics saw a increase in short interest in September. As of September 30th, there was short interest totalling 1,430,000 shares, an increase of 11.7% from the August 30th total of 1,280,000 shares. Based on an average trading volume of 117,300 shares, the short-interest ratio is currently 12.2 days. Currently, 4.9% of the company's stock are sold short. View Odonate Therapeutics' Current Options Chain.

Who are some of Odonate Therapeutics' key competitors?

What other stocks do shareholders of Odonate Therapeutics own?

Who are Odonate Therapeutics' key executives?

Odonate Therapeutics' management team includes the folowing people:
  • Mr. Kevin C. Tang, Chairman & CEO (Age 52)
  • Mr. John G. Lemkey, Chief Operating Officer (Age 38)
  • Dr. Joseph P. O'Connell M.D., Chief Medical Officer (Age 65)
  • Mr. Michael S. Hearne, CFO & Principal Accounting Officer (Age 57)
  • Dr. Steven S. Pfeiffer Ph.D., VP of Technical Operations (Age 43)

When did Odonate Therapeutics IPO?

(ODT) raised $150 million in an initial public offering (IPO) on Thursday, December 7th 2017. The company issued 5,900,000 shares at $24.00-$27.00 per share. Goldman Sachs and Jefferies served as the underwriters for the IPO and Cowen was co-manager.

How do I buy shares of Odonate Therapeutics?

Shares of ODT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Odonate Therapeutics' stock price today?

One share of ODT stock can currently be purchased for approximately $26.95.

How big of a company is Odonate Therapeutics?

Odonate Therapeutics has a market capitalization of $867.52 million. The company earns $-88,960,000.00 in net income (profit) each year or ($3.64) on an earnings per share basis. Odonate Therapeutics employs 117 workers across the globe.View Additional Information About Odonate Therapeutics.

What is Odonate Therapeutics' official website?

The official website for Odonate Therapeutics is http://www.odonate.com/.

How can I contact Odonate Therapeutics?

Odonate Therapeutics' mailing address is 4747 EXECUTIVE DRIVE SUITE 510, SAN DIEGO CA, 92121. The company can be reached via phone at 858-731-8180 or via email at [email protected]


MarketBeat Community Rating for Odonate Therapeutics (NASDAQ ODT)

Community Ranking:  2.0 out of 5 (star star)
Outperform Votes:  114 (Vote Outperform)
Underperform Votes:  166 (Vote Underperform)
Total Votes:  280
MarketBeat's community ratings are surveys of what our community members think about Odonate Therapeutics and other stocks. Vote "Outperform" if you believe ODT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ODT will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 10/19/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel